Avalon GloboCare Establishes Joint Venture with Arbele Limited to Co-develop Next-Generation Multi-Targeted CAR-T Cellular Im...
January 03 2019 - 9:00AM
Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer
of cell-based technologies, announced today that the Company and
its wholly owned subsidiary, Avactis Biosciences, have entered into
a joint venture and exclusive license agreement with Arbele Limited
to co-develop next generation, transposon-based Chimeric Antigen
Receptor (CAR)-T and CAR-Natural Killer (NK) cellular
therapies. These unique CAR vector constructs are non-virally
engineered, possessing multiple therapeutic targets as well as
unique “safety-switch" mechanisms. Based on Avalon’s
extensive hospital network for cellular therapy, together with the
Company’s established GMP bio-production facility in China (Epicon
Biotech, Nanjing), this joint venture allows Avalon to accelerate
the clinical development of more efficacious and safer CAR-T/CAR-NK
therapies, such as those developed by Arbele.
“We are very excited to establish this joint
venture with Arbele Limited to accelerate our clinical programs in
cellular therapy,” stated David Jin, M.D., Ph.D., CEO and President
of Avalon GloboCare Corp. “Arbele’s strong proprietary
technology platform in designing and production of non-viral,
transposon-engineered, multi-targeted CAR will allow us to generate
next-generation, better and safer CAR-T and CAR-NK cellular
therapeutics. This joint venture will strengthen our core
technological capabilities, enrich our intellectual properties, as
well as further establish our leadership in the field of cellular
immunotherapy,” added Dr. Jin.
About Arbele Limited
Arbele Limited, founded by industry veterans
from Roche, Johnson & Johnson and ICOS Corporation, is a
biopharmaceutical company focusing on acceleration and expansion of
immunotherapy technology and product development to treat advanced
stages of cancers, including those most prevalent in the USA,
Australia and the Asia-Pacific region. Arbele Limited has
headquarters located in the Hong Kong Science and Technology Park,
with its state-of-the-art research hub, Arbele Corp., located in
Seattle, WA. Arbele Limited currently holds multiple promising
“first-in-class” immuno-oncology candidates (including monoclonal
and bi-specific antibodies) within its pipeline. Notably, Arbele’s
unique non-viral, transposon-based T cell engineering technology is
an exceptional system for rapid delivery of CAR-T cell
therapeutics. Later in 2019, phase I clinical studies will be
conducted in Australia for refractory or advanced gastrointestinal
cancers (including colon, stomach and pancreatic), as well as via
joint venture with Avalon GloboCare Corp. for clinical development
of CAR-T cellular therapy in China.
About Avalon GloboCare Corp.
Avalon GloboCare Corp. (NASDAQ: AVCO) is a
global intelligent biotech developer and healthcare service
provider dedicated to promoting and empowering high impact,
transformative cell-based technologies and their clinical
applications, as well as healthcare facility management through its
core platforms, namely "Avalon Cell" and "Avalon Rehab." In
addition, Avalon provides strategic advisory and outsourcing
services to facilitate and enhance their clients' growth,
development, as well as competitiveness in both domestic and global
healthcare markets. Avalon also engages in the management of stem
cell banks and specialty clinical laboratories. Through its U.S.
subsidiaries, namely GenExosome Technologies Inc. and Avactis
Biosciences Inc., Avalon will further establish our leading roles
in the fields of cellular immunotherapy (including CAR-T/CAR-NK),
liquid biopsy, precision medicine and regenerative medicine.
Forward-Looking Statements
Certain statements contained in this press
release may constitute "forward-looking
statements." Forward-looking statements provide current
expectations of future events based on certain assumptions and
include any statement that does not directly relate to any
historical or current fact. Actual results may differ materially
from those indicated by such forward-looking statements as a result
of various important factors as disclosed in our filings with the
Securities and Exchange Commission located at their website
(http://www.sec.gov). In addition to these factors, actual future
performance, outcomes, and results may differ materially because of
more general factors including (without limitation) general
industry and market conditions and growth rates, economic
conditions, and governmental and public policy changes. The
forward-looking statements included in this press release represent
the Company's views as of the date of this press release and these
views could change. However, while the Company may elect to update
these forward-looking statements at some point in the future, the
Company specifically disclaims any obligation to do so. These
forward-looking statements should not be relied upon as
representing the Company's views as of any date subsequent to the
date of the press release.
Contact Information: Avalon GloboCare
Corp. 4400 Route 9, Suite 3100 Freehold, NJ 07728
PR@Avalon-GloboCare.com
Investor Relations: Crescendo Communications,
LLC Tel: (212) 671-1020 avco@crescendo-ir.com
Avalon GloboCare (NASDAQ:AVCO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Avalon GloboCare (NASDAQ:AVCO)
Historical Stock Chart
From Sep 2023 to Sep 2024